

CLEAR YOUR VIEW

Biomarker Testing Is Driving a New Standard of Care for Advanced Lung Cancer



Patty Watkins

Stage IV non-small cell lung cancer survivor

The Clear Your View initiative encourages oncologists to conduct complete biomarker testing for *all* advanced non-small cell lung cancer (NSCLC) patients.

Biomarker-driven targeted therapies and precision medicine are extending survival for advanced lung cancer patients¹⁻⁷

Complete biomarker testing results can help determine what treatments will be of most benefit and which may be ineffective.



AJ Patel

Stage IV lung
cancer survivor

Complete biomarker testing saved AJ's life

AJ was diagnosed with stage IV non-small cell lung cancer. After a brain scan showed that he also had brain tumors, he was given just six months to live. While waiting for surgery, AJ had biomarker testing, which revealed he had a targetable biomarker. Today, AJ is doing well and frequently meets with state legislators to talk about the importance of complete biomarker testing.

More than 80% of advanced lung cancer patients do not receive complete guideline-recommended biomarker testing, putting them at risk for inappropriate treatment⁸

Advanced lung cancer patients with targetable biomarkers get little benefit from immunotherapy compared with targeted therapy.⁹

Response Rates⁹⁻¹⁵

Targeted Therapy	50–83%
Immunotherapy	4–26%

Guidelines recommend testing for 10 biomarkers before initiating treatment for NSCLC

Several NSCLC biomarkers can be targeted by a growing list of FDA-approved therapies.



Patty Watkins

Stage IV lung
cancer survivor

Biomarker testing helped Patty get on the right track

When Patty, a stage IV NSCLC patient, was told that she had only a few days to live, she had only one thing in mind: attending her son's graduation. After her first treatment didn't work, Patty received complete biomarker testing that identified a ROS1 mutation. She received a targeted treatment and, later, had additional biomarker testing that found a new mutation. Patty was put on an investigational targeted treatment and continues to do well today. She not only made it to her son's graduation, she got to hold her first grandchild.

One chance to make the right decision

There may be just one opportunity for a doctor to make the right decision about a patient's first-line treatment for advanced NSCLC.

Only 1 in 2 NSCLC patients make it to receive second-line therapy¹⁶⁻¹⁷

Join us in committing to complete biomarker testing for all NSCLC patients

www.ClearYourView.org

References:

1. Shaw AT et al. Annals of Oncol. 2019.
2. Ramalingam SS et al. Annals of Oncol. 2019.
3. Garon EB et al. J Clin Oncol. 2019.
4. Camidge DR et al. J Thorac Oncol. 2019.
5. Planchard D et al. Lancet Oncol. 2017.
6. Gadgeel SM J Clin Oncol. 2019.
7. Sandler A et al. N Engl J Med. 2006.
8. Leighl NB et al. Clin Cancer Res. 2019.
9. NCCN. Non–Small Cell Lung Cancer Guidelines. 2020.
10. Mack PC et al. Cancer 2020.
11. Gettinger S et al. J Clin Oncol. 2016.
12. Peters S et al. J Clin Oncol. 2017.
13. Gainor JF et al. Clin Cancer Res. 2016.
14. Dudnik E et al. J Thorac Oncol. 2018.
15. Guisier F et al. J Thorac Oncol. 2019.
16. Aggarwal C et al. JAMA Oncol. 2019.
17. Hagemann IA et al. Cancer. 2015.

Advocacy Partners:



Industry Sponsor:

